UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

OP23 New therapeutics for myelodysplastic syndromes (MDS)

Leukemia research, 2007, Vol.31, p.S43-S44

List, A.F

2007

Volltextzugriff (PDF)

15 Active treatment – improving outcomes in del 5q patients

Leukemia research, 2007, Vol.31, p.S9-S9

List, A.F

2007

Volltextzugriff (PDF)

Impact of Gene Mutations on Response to Lenalidomide and OS in Lower-Risk Non-Del(5Q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (ESAS)

Leukemia research, 2017-04, Vol.55, p.S14-S14

2017

Volltextzugriff (PDF)

Chromosomal Aberrations in Therapy-Related Myelodysplastic Syndromes – Relations to Primary Disease, Therapy and Prognostic Significance

Leukemia research, 2017-04, Vol.55, p.S32-S33

2017

Volltextzugriff (PDF)

217 DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE

Leukemia research, 2015-04, Vol.39, p.S109-S109

2015

Volltextzugriff (PDF)

10 Guidelines for immunosuppression in MDS

Leukemia research, 2011, Vol.35, p.S4-S4

2011

Volltextzugriff (PDF)

14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION

Leukemia research, 2015-04, Vol.39, p.S5-S6

2015

Volltextzugriff (PDF)

P-061 Optimization of telomerase reverse transcriptase as a molecular diagnostic in MDS

Leukemia research, 2013-05, Vol.37, p.S49-S50

2013

Volltextzugriff (PDF)

P-229 GM-CSF-dependent pSTAT5 Sensitivity is a Feature of chronic myelomonocytic leukemia and a therapeutic target

Leukemia research, 2013-05, Vol.37, p.S126-S126

2013

Volltextzugriff (PDF)

P-100 Validation of the Revised International Prognostic Scoring System (IPSS-R) and its therapeutic implications

Leukemia research, 2013-05, Vol.37, p.S67-S68

2013

Volltextzugriff (PDF)

JAK2V617F mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones

Leukemia research, 2010-06, Vol.34 (6), p.821-823

2010

Volltextzugriff (PDF)

276 Outcome of azacitidine treatment of patients with therapy related myelodysplastic syndrome

Leukemia research, 2011, Vol.35, p.S108-S109

2011

Volltextzugriff (PDF)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

Annals of oncology, 2016-01, Vol.27 (1), p.62-68

2016

Volltextzugriff (PDF)

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

Leukemia, 2013-06, Vol.27 (6), p.1301-1309

2013

Volltextzugriff (PDF)

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Leukemia, 2013-05, Vol.27 (5), p.1072-1079

2013

Volltextzugriff (PDF)

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

Leukemia, 2010-10, Vol.24 (10), p.1799-1804

2010

Volltextzugriff (PDF)

4 Controlling the “fate” of T cells in MDS

Leukemia research, 2009-05, Vol.33, p.S1-S2

2009

Volltextzugriff (PDF)

C028 Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion

Leukemia research, 2007, Vol.31, p.S38-S38

2007

Volltextzugriff (PDF)

P049 Impaired T cell function and reduced peripheral tolerance mechanisms in myelodysplastic syndrome (MDS)

Leukemia research, 2007, Vol.31, p.S67-S67

2007

Volltextzugriff (PDF)

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide

Leukemia, 2016-12, Vol.30 (12), p.2405-2409

2016

Volltextzugriff (PDF)

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del

Leukemia, 2015-12, Vol.29 (12), p.2452

2015

Volltextzugriff (PDF)

P122 Value of transfusion-free living in myelodysplastic syndromes (MDS): results of health utility interviews with patients

Leukemia research, 2007, Vol.31, p.S105-S106

2007

Volltextzugriff (PDF)

24 - Impact of Gene Mutations on Response to Lenalidomide and OS in Lower-Risk Non-Del(5Q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (ESAS)

Leukemia research, 2017-04, Vol.55, p.S14-S14

2017

Volltextzugriff (PDF)

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

Leukemia, 2013-04, Vol.27 (4), p.977-980

2013

Volltextzugriff (PDF)

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Leukemia, 2015-12, Vol.29 (12), p.2452-2452

2015

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(16)
Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Humans
(12)
Oncology
(12)
Hematology
(11)
Leukemia
(9)
Cancer Research
(8)
Critical Care Medicine
(8)
Intensive
(8)
Internal Medicine
(8)
Medicine
(8)
Medicine & Public Health
(8)
Medicine/public Health
(8)
Aged
(7)
Female
(7)
Middle Aged
(7)
Myelodysplastic Syndromes
(7)
Aged, 80 And Over
(6)
Mutation
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

OP23 New therapeutics for myelodysplastic syndromes (MDS)

15 Active treatment – improving outcomes in del 5q patients

Impact of Gene Mutations on Response to Lenalidomide and OS in Lower-Risk Non-Del(5Q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (ESAS)

Chromosomal Aberrations in Therapy-Related Myelodysplastic Syndromes – Relations to Primary Disease, Therapy and Prognostic Significance

217 DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE

10 Guidelines for immunosuppression in MDS

14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION

P-061 Optimization of telomerase reverse transcriptase as a molecular diagnostic in MDS

P-229 GM-CSF-dependent pSTAT5 Sensitivity is a Feature of chronic myelomonocytic leukemia and a therapeutic target

P-100 Validation of the Revised International Prognostic Scoring System (IPSS-R) and its therapeutic implications

JAK2V617F mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones

276 Outcome of azacitidine treatment of patients with therapy related myelodysplastic syndrome

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

4 Controlling the “fate” of T cells in MDS

C028 Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion

P049 Impaired T cell function and reduced peripheral tolerance mechanisms in myelodysplastic syndrome (MDS)

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del

P122 Value of transfusion-free living in myelodysplastic syndromes (MDS): results of health utility interviews with patients

24 - Impact of Gene Mutations on Response to Lenalidomide and OS in Lower-Risk Non-Del(5Q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (ESAS)

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Suchergebnisse filtern